Long gone are the days this 1970 Plymouth Barracuda rocked its factory drivetrain and power. Now, it comes down the drag ...
MSD is expecting to see an additional $200 million layered onto its costs this year as a result of President Trump's tariffs – even before a possible pharma-specific levy is announced. The US pharma ...
TipRanks on MSN
Evaxion Out-Licenses Vaccine Candidate EVX-B3 to MSD
Evaxion Biotech ( ($EVAX) ) just unveiled an announcement. On September 25, 2025, Evaxion A/S announced the out-licensing of its vaccine candidate ...
Pharmaceutical Technology on MSN
MSD pays up to nearly $600m for Evaxion’s mystery vaccine candidate
Evaxion’s preclinical asset targets an unknown infectious disease in which there are no other vaccines available.
MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage ...
This company is known for being overpriced and uncooperative, making it the least friendly in the industry. They make it very hard to cancel services, often requiring a court order, and even then, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback